Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

Shelley Wood

December 31, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2018

Shelley Wood

July 02, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2018

Caitlin E. Cox

June 01, 2018

News Industry News

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

November 14, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News Stories for 2015

Shelley Wood

December 29, 2015

News Opinion Editor's Corner

Las 10 Noticias de TCTMD Más Leídas de 2015

Shelley Wood

December 29, 2015

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Daily News

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

Todd Neale

October 26, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Todd Neale

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

Todd Neale

October 26, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

Presentation

RE-VERSE AD: Idarucizumab for Dabigatran Reversal

Presenter: Charles V. Pollack Jr

June 24, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

Advertisement

The Biggest News of 2018: TCTMD’s Top 10

TCTMD’s Top 10 Most Popular Stories for June 2018

TCTMD’s Top 10 Most Popular Stories for May 2018

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

TCTMD’s Top 10 Most Popular News Stories for 2015

Las 10 Noticias de TCTMD Más Leídas de 2015

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

RE-VERSE AD: Idarucizumab for Dabigatran Reversal

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content